Literature DB >> 2824273

Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.

K Yamada1.   

Abstract

The chemosensitivity of human colorectal cancer was studied in relation to the biological features of the tumor using a human tumor/nude mouse in-vivo system. The biological features included the histological type, growth rate, mucus secretion and productivity of CEA of the tumor. The overall sensitivity to four anticancer agents examined (5-FU, MMC, CPA and CDDP) was relatively insignificant. The heterogeneity of chemosensitivity among primary, metastatic and recurrent lesions of the same patient was demonstrated. A tumor line obtained from poorly differentiated adenocarcinoma showed better responses to 3 of 4 agents. Tumor doubling time evaluated as an indicator of tumor growth rate showed a significant correlation with sensitivity to MMC. The time also showed a tendency to correlate with sensitivity to CDDP. The tumor with shorter tumor doubling time presented had more remarkable sensitivity to such agents. Similar correlation was observed in the mucus secretion shown by Alcian-blue (AB) staining and sensitivity to MMC and CDDP. Tumors with less significant AB staining showed more remarkable sensitivity to these agents. The productivity of CEA revealed a tendency to correlate with sensitivity to MMC and CPA. These results indicated that histological type, growth rate, mucus secretion by AB staining and productivity of CEA of the tumor might be parameters of chemosensitive differences of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824273     DOI: 10.1007/BF02776719

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  24 in total

1.  Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice.

Authors:  T Kubota; M Nakada; K Tsuyuki; T Inada; F Asanuma; K Ishibiki; O Abe
Journal:  Jpn J Cancer Res       Date:  1986-05

2.  Concepts for systemic treatment of micrometastases.

Authors:  F M Schabel
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

3.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

4.  Adjuvant chemotherapy in the surgical treatment of large bowel cancer.

Authors:  G A Higgins; E Humphrey; G Juler; H H LeVeen; J McCaughan; R J Keehn
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

5.  Carcinoma of the colon and rectum--growth rate.

Authors:  S Bolin; E Nilsson; R Sjödahl
Journal:  Ann Surg       Date:  1983-08       Impact factor: 12.969

Review 6.  [Treatment of carcinoma and chronology (study of time) of cancer].

Authors:  S Kusama
Journal:  Gan To Kagaku Ryoho       Date:  1982-04

7.  Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay.

Authors:  P Schlag; W Schreml
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

8.  CEA monitoring of palliative treatment for colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke; A Mittelman
Journal:  Ann Surg       Date:  1977-01       Impact factor: 12.969

9.  Establishment and characterization of human colorectal cancer cell lines.

Authors:  J A McBain; J L Weese; L F Meisner; W H Wolberg; J K Willson
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient.

Authors:  M Fujita; S Hayata; T Taguchi
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

View more
  1 in total

1.  Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation?

Authors:  A Vergeylen; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.